Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 487 (TSXV: $META.V) (CSE: $HITI.C) (OTCQB: $HITIF) (OTC: $CHNC)
Today's podcast sponsored by Cannabis Suisse Corp.
(OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in
Switzerland
Delta, Kelowna, BC, October 28, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/102820-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10281META-HITI-HITIF-CHNC.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s podcast is
sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's facilities for producing cannabis
are based in Dietikon, Switzerland, and contain the art surveillance equipment
to enable an around the clock webcast. Cannabis Suisse grows high quality,
organic cannabis with sustainable, all-natural principles. The Company's
products are laboratory tested to ensure the end users have access to a
standardized, safe and consistent product. Cannabis Suisse proprietary
trademarked MoldStandard is a quantitative microbiology method for analyzing
yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary
trademarked CannaMec is a method for quantifying and removing residual solvents
during packaging and storage of CBD products. Cannabis Suisse Corp. currently
sells via a distribution network of Swiss retailers and online shops, under the
retail brand Alpine Cannabis.
In
today’s podcast we look at a few public and private company announcements.
Meta
Growth Corp. (TSXV: META) and High Tide Inc. (CSE: HITI) (OTCQB: HITIF) announced that, at the special meeting of
shareholders of META held yesterday, the shareholders of META voted in favour
of a special resolution to approve the previously announced proposed business
combination pursuant to which High Tide will acquire all of the issued and
outstanding common shares of META by way of a plan of arrangement under the Business Corporations Act, as further
described in the joint news release issued by META and High Tide on August 21,
2020. The Arrangement required approval by 66 ⅔% of the votes cast by META shareholders
present in person or represented by proxy at the Meeting.
The Arrangement will create:
● Canada's Largest Cannabis Retailer with
$1481 million in Annualized Revenue
● Annual Cost and Operational Synergies of
Approximately $8 million to $9 million
● A strong Balance Sheet to Support Growth
A total of 102,113,758 META Shares,
representing approximately 43.1% of the outstanding META Shares, were
represented in person or by proxy at the Meeting. Of the votes cast with
respect to the Arrangement, an aggregate of 102,063,111 META Shares were voted
in favour of the Arrangement, representing approximately 99.95% of the votes
cast on the resolution approving the Arrangement.
It is expected that META will apply
for a final order from the Court of Queen's Bench of Alberta in respect of the
Arrangement on October 28, 2020. Completion of the Arrangement remains subject
to receipt of required regulatory and court approvals and other customary
closing conditions, which are set out in the arrangement agreement between META
and High Tide dated August 20, 2020, a copy of which can be found on the SEDAR
profiles of META and High Tide at www.sedar.com. Assuming that the conditions to
closing of the Arrangement are satisfied or waived, it is anticipated that the
Arrangement will be completed on or before the end of November. Further
information about the Arrangement is set forth in the materials prepared by
META in respect of the Meeting, which were mailed to META shareholders and
filed under META's profile on SEDAR at www.sedar.com.
Ikänik
Farms, Inc. announced that its wholly owned, CBD-focused
subsidiary, Ikänik Life has expanded its action sports family with the addition
of snowboarding phenom, Toby Miller.
"We are excited to welcome Toby
to the Ikänik family and participate in his athletic progression. Toby's love
for snowboarding is contagious and his unique approach to competing in the
halfpipe makes him a global fan favorite," said Brian Baca, CEO of Ikänik
Farms.
Toby kicked off his professional
career by winning the USASA Nationals title and major sponsors by the age of
13. His career trajectory has continued to over the years, with 2018 being a
breakout season for Miller, as he exploded onto the pro scene and made a
statement by owning three podiums in major halfpipe competitions. Last season,
Toby stole the show at X Games in Aspen, Colorado and won a bronze medal in the
men's snowboarding halfpipe event.
Toby is focusing on the 2022 Olympic
Games in China, with an intense training regimen that is preparing him both
mentally and physically to be a leader, in his first of many winter Olympics.
He trains with Ikänik Farms board member and US Snowboarding coach JJ Thomas,
alongside Shaun White. Toby and Shaun have been riding together since he was 13
years old, and now they will be pushing each other as they each try to earn a
spot on the US Olympic halfpipe team this season.
"I'm grateful to have partnered
up with Ikänik Life CBD to help maintain longevity in the sport I love,"
said Miller. "Focusing on personal care and training is my top
priority."
China
Infrastructure Construction Corp. (OTC:CHNC) announced its merger with Pharmacology
University, Inc., a global leader in the field of medical cannabis education
that markets its services under the brand Pharmacology University. More to the
point, CHNC joining forces with Pharmacology University Inc. and Precision
Research Institute has created one of the most complete companies in the
cannabis industry. COO Elizabeth Hernandez explains the reasons behind the
decision: “While pursuing my dream, I had wanted to unite forces with a company
in the Cannabis Industry and that is when I found Pharmacology University. The
synergy between the two companies has been superb and we are positioning
ourselves to become the high-end authority of the Cannabis Research Industry.
Now this journey finally feels complete. Riding this new wave of inspiration,
we are deeply committed to produce revenue generating models and building
shareholder value.”
The merger of CHNC, which is
publicly traded on OTC markets under the ticker symbol CHNC, provides the
framework for Pharmacology University to expand its focus into cannabis
clinical trials and bolstering its education offerings.
Founded in 2010, Pharmacology
University offers educational products and consulting services in the United
States, Puerto Rico, Latin and South America; to train doctors, dispensary
owners, growers, lawyers, and other professionals on the palliative and myriad
health benefits of cannabis. The company also has partnered with private
accredited universities to offer an intensive master's certification program in
cannabis science and is now the top international provider of medical cannabis
education.
In addition to its classroom
education, Pharmacology University owns and operates Canna Law Magazine, which
is a digital informational piece that provides cultural enrichment to the
cannabis entrepreneur. The magazine has biweekly editions and informs the
public about the most recent legal cases in the cannabis industry worldwide,
also providing strategies by which its readers can avoid finding themselves in
legal situations for lack of knowledge. Canna Law Magazine is currently
available in English, Spanish, Portuguese, Italian and Arabic, and it is being
developed to be published in Chinese and Hindi. To view the magazine, visit www.cannalawmagazine.com.
“We want to be pioneers in the
search for the truth with actual clinical trials, in regards to how cannabis
can be utilized,” says Pharmacology University In-House Legal Counsel, Anne
Graham. “Predominantly because the number one problem for people that are set
against using cannabis as medicine is simply due to the fact that the cannabis
industry has not produced sufficient medical studies,” she says.
The global market for medical
cannabis (also known as medical marijuana), is expected to reach more than $150
billion annually by 2027, according to a 2019 report by ResearchAndMarkets.com.
The anticipated growth is driven in large part by the legalization of cannabis
for medical use in Europe, as well as the passage in the U.S. of the Hemp
Farming Act of 2018, which legalized hemp, a variety of the Cannabis Sativa
species that has less than 0.3% concentration of tetrahydrocannabinol (THC).
And although many companies are looking to capitalize on the industry’s projected
growth by opening dispensaries, cannabis farms, or manufacturing facilities,
Pharmacology University sees limitless opportunities in the education space.
Says Dr. Jose Torres, International
Medical Director for Pharmacology University, “The endocannabinoid system is
represented in every organ and system in the body. That means that at times, we
could have deficiencies, just like now and again, our bodies present
insufficiencies of minerals and vitamins; accordingly, the human body could
also lack endocannabinoids.” Preliminary research indicates that the scarcity
of endocannabinoids may be the root of various illnesses, such as epilepsy and
even certain types of cancer, he adds. By becoming a pioneer in clinical trials
to explore more than 120 cannabis molecules, the newly formed public company
aims to equip healthcare professionals and others in the industry with the
information and knowledge to help millions of people through the use of
cannabis in medical treatments.
“We had a vision when we started ten
years ago, and 2021 will be our dream becoming a reality,” says Katerin Osuna,
International Director of Marketing and Public Relations of Pharmacology
University, Magister in Audiovisual Communications and Advertising Content,
from the Autónoma University of Barcelona, Spain. “We look forward to being the
world leader in cannabis clinical studies.”
The
Mental Health Commission of Canada (MHCC) announced funding 14 community-based research
projects that will explore how cannabis use affects underserved populations
across the country. Each project will receive funding of up to $100,000 over
two years, for a total research investment of $1.4 million.
Following the community-based
research model, each community under study will lead its own project,
participate in every phase of the research, and benefit from positive social
change that occurs as a result of the findings.
"We are excited to see
community-based research projects across Canada that will build capacity and
new knowledge, directly benefit communities, and influence public policy,"
said Dr. Joanna Ochocka, co-director at the Centre for Community Based Research
(CCBR). "Collectively, these projects could create stronger, more
responsive and supportive communities, especially for those people who lack
power or opportunity or who are vulnerable in some way."
The projects will address
significant gaps in research on cannabis and mental health among Indigenous,
Métis, 2SLGBTQ+, senior, immigrant, refugee, ethnocultural, and racialized
(IRER) populations, as well as other communities who experience layers of
oppression.
One example is the initiative to be
undertaken by the Centre for Resilience and Social Development (CRSD).
"It's important to examine the link between mental health and cannabis use
through social, political and economic lenses," said CRSD project manager
Aber Abdulle, who will be looking at how these factors intersect among IRER
populations, while striving to bolster community engagement and empower young
people.
Six of the projects will include
initial examinations of cannabis use and mental health in Métis and First
Nations communities – some of the first Indigenous-led research of its kind.
"These six projects offer an
opportunity for First Nations and Métis to invest in research that honours
their own language and culture, the foundation of their world views," said
Dr. Carol Hopkins, executive director at the Thunderbird Partnership Foundation.
"That's a step in the right direction toward the decolonization of
Indigenous knowledges."
For Krista Benes, director of the
MHCC's mental health and substance use team, this investment marks an exciting
step toward more inclusive research. "No one is better equipped to explore
the relationship between cannabis and mental health in marginalized communities
than the people from those communities. We're all experts in our own
right."
Quick
Facts
● Six of
the 14 funded projects are Indigenous-led.
● This research
will be the first to examine cannabis use and mental health in Métis
communities.
● This
research will be among the first Indigenous-led examinations of cannabis use
and mental health.
Research led by Philippe Lucas, a Graduate Researcher at the University of Victoria
and VP Global Patient Research and
Access at Tilray, announced that his research has found that
medical cannabis use is associated with self-reported reductions and even
discontinuation of alcohol use amongst authorized Canadian patients.
The results stem from the Canadian
Cannabis Patient Survey 2019 (CCPS 2019), a large national cross-sectional
survey that gathered comprehensive information on patient demographics,
patterns of cannabis use, and self-reported use of prescription drugs, alcohol,
tobacco, and illicit drugs before and after medical cannabis initiation from
2102 Canadian medical cannabis patients registered with Tilray, a global
pioneer in medical cannabis research and production.
"The results of CCPS 2019 add
to a growing body of evidence that medical cannabis use is often associated
with reductions in the use of other substances, including alcohol, opioids,
tobacco and illicit drugs" says Lucas. "Since alcohol is the most
prevalent recreational substance in the world, and its use results in
significant rates of criminality, morbidity and mortality, these findings may
result in improved health outcomes for medical cannabis patients, as well as
overall improvements in public health and safety."
These results were recently
published in the International Journal of Drug Policy in a paper titled Reductions in
alcohol use following medical cannabis initiation: results from a large
cross-sectional survey of medical cannabis patients in Canada
co-authored by Susan Boyd (University of Victoria), M-J Milloy (University of
British Columbia) and Zach Walsh (University of British Columbia, Okanagan).
Overall, 973 survey participants reported past or current alcohol use, with 419 (44%) reporting decreases in alcohol usage frequency over 30 days, 323 (34%) decreasing the number of standard drinks they had per week, and 76 (8%) reporting no alcohol use at all in the 30 days prior to the survey. Being younger than 55 years and reporting higher rates of alcohol use prior to initiating medical cannabis use were both associated with greater odds of reducing alcohol use, and having an intention to use medical cannabis to reduce alcohol consumption was associated with significantly greater odds of both reducing and ceasing alcohol use altogether.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using
our list of
top stock trading apps including Robinhood, Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on
Investorideas.com
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
No comments:
Post a Comment